Skip to main content
Top
Published in: Clinical and Translational Oncology 7/2018

Open Access 01-07-2018 | Special Article

SEOM–SERAM–SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer

Authors: G. Fernández-Pérez, R. Sánchez-Escribano, A. M. García-Vicente, A. Luna-Alcalá, J. Ceballos-Viro, R. C. Delgado-Bolton, J. C. Vilanova-Busquets, P. Sánchez-Rovira, M. P. Fierro-Alanis, R. García-Figueiras, J. E. Alés-Martínez

Published in: Clinical and Translational Oncology | Issue 7/2018

Login to get access

Abstract

Imaging in oncology is an essential tool for patient management but its potential is being profoundly underutilized. Each of the techniques used in the diagnostic process also conveys functional information that can be relevant in treatment decision-making. New imaging algorithms and techniques enhance our knowledge about the phenotype of the tumor and its potential response to different therapies. Functional imaging can be defined as the one that provides information beyond the purely morphological data, and include all the techniques that make it possible to measure specific physiological functions of the tumor, whereas molecular imaging would include techniques that allow us to measure metabolic changes. Functional and molecular techniques included in this document are based on multi-detector computed tomography (CT), 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), magnetic resonance imaging (MRI), and hybrid equipments, integrating PET with CT (PET/CT) or MRI (PET-MRI). Lung cancer is one of the most frequent and deadly tumors although survival is increasing thanks to advances in diagnostic methods and new treatments. This increased survival poises challenges in terms of proper follow-up and definitions of response and progression, as exemplified by immune therapy-related pseudoprogression. In this consensus document, the use of functional and molecular imaging techniques will be addressed to exploit their current potential and explore future applications in the diagnosis, evaluation of response and detection of recurrence of advanced NSCLC.
Literature
1.
go back to reference Stephen RM, Gillies RJ. Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm Res. 2007;24:1172–85.CrossRefPubMed Stephen RM, Gillies RJ. Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm Res. 2007;24:1172–85.CrossRefPubMed
2.
go back to reference Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;4(304):1497–500.CrossRef Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;4(304):1497–500.CrossRef
3.
go back to reference Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. Engl J Med. 2010;28(363):1693–703.CrossRef Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. Engl J Med. 2010;28(363):1693–703.CrossRef
5.
go back to reference Du L, Herbst RS, Morgensztern D. Immunotherapy in lung cancer. Hematol Oncol Clin North Am. 2017;31:131–41.CrossRefPubMed Du L, Herbst RS, Morgensztern D. Immunotherapy in lung cancer. Hematol Oncol Clin North Am. 2017;31:131–41.CrossRefPubMed
6.
go back to reference Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;1(33):3541–3.CrossRef Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;1(33):3541–3.CrossRef
7.
go back to reference Lee HY, Choi YL, Lee KS, Han J, Zo JI, Shim YM, et al. Pure ground-glass opacity neoplastic lung nodules: histopathology, imaging and management. AJR Am J Roentgen. 2014;202:W224–33.CrossRef Lee HY, Choi YL, Lee KS, Han J, Zo JI, Shim YM, et al. Pure ground-glass opacity neoplastic lung nodules: histopathology, imaging and management. AJR Am J Roentgen. 2014;202:W224–33.CrossRef
8.
go back to reference Naidich DP, Bankier AA, MacMahon H, Schaefer-Prokop CM, Pistolesi M, Goo AM, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology. 2013;266:304–17.CrossRefPubMed Naidich DP, Bankier AA, MacMahon H, Schaefer-Prokop CM, Pistolesi M, Goo AM, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology. 2013;266:304–17.CrossRefPubMed
9.
go back to reference Chen L, Zhang J, Bao J, et al. Meta-analysis of diffusion-weighted MRI in the differential diagnosis of lung lesions. J Magn Reson Imaging. 2013;37:1351–8.CrossRefPubMed Chen L, Zhang J, Bao J, et al. Meta-analysis of diffusion-weighted MRI in the differential diagnosis of lung lesions. J Magn Reson Imaging. 2013;37:1351–8.CrossRefPubMed
10.
go back to reference Luna A, Sánchez-Gonzalez J, Caro P. Diffusion-weighted imaging of the chest. Magn Reson Imaging Clin N Am. 2011;19:69–94.CrossRefPubMed Luna A, Sánchez-Gonzalez J, Caro P. Diffusion-weighted imaging of the chest. Magn Reson Imaging Clin N Am. 2011;19:69–94.CrossRefPubMed
11.
go back to reference Lee HY, Jeong JY, Lee KS, et al. Histopathology of lung adenocarcinoma based on new IASLC/ATS/ERS classification: prognostic stratification with functional and metabolic imaging biomarkers. J Magn Reson Imaging. 2013;38:905–13.CrossRefPubMed Lee HY, Jeong JY, Lee KS, et al. Histopathology of lung adenocarcinoma based on new IASLC/ATS/ERS classification: prognostic stratification with functional and metabolic imaging biomarkers. J Magn Reson Imaging. 2013;38:905–13.CrossRefPubMed
12.
go back to reference Glastonbury CM, Bhosale PR, Choyke PL, D’Orsi CJ, Erasmus JJ, Gill RR, et al. Do radiologists have stage fright? Tumor staging and how we can add value to the care of patients with cancer. Radiology. 2016;278:11–2.CrossRefPubMed Glastonbury CM, Bhosale PR, Choyke PL, D’Orsi CJ, Erasmus JJ, Gill RR, et al. Do radiologists have stage fright? Tumor staging and how we can add value to the care of patients with cancer. Radiology. 2016;278:11–2.CrossRefPubMed
13.
go back to reference Eberhardt WEE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26:1573–88.CrossRefPubMed Eberhardt WEE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26:1573–88.CrossRefPubMed
14.
go back to reference Camps C, Felip E, García-Campelo R, Trigo JM, Garrido P. SEOM clinical guidelines for the treatment of non-small cell lung cancer. Clin Transl Oncol. 2013;15:977–84.CrossRefPubMed Camps C, Felip E, García-Campelo R, Trigo JM, Garrido P. SEOM clinical guidelines for the treatment of non-small cell lung cancer. Clin Transl Oncol. 2013;15:977–84.CrossRefPubMed
15.
go back to reference Lewis SZ, Diekemper R, Addrizzo-Harris DJ. Methodology for the development of guidelines for lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(suppl):41–50.CrossRef Lewis SZ, Diekemper R, Addrizzo-Harris DJ. Methodology for the development of guidelines for lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(suppl):41–50.CrossRef
16.
go back to reference Smoragiewicz M, Laskin J, Wilson D, Ramsden K, Yee J, Lam S, et al. Using PET/CT to reduce futile thoracotomy rates in non-small-cell lung cancer: a population-based review. Curr Oncol. 2014;21:768–74.CrossRef Smoragiewicz M, Laskin J, Wilson D, Ramsden K, Yee J, Lam S, et al. Using PET/CT to reduce futile thoracotomy rates in non-small-cell lung cancer: a population-based review. Curr Oncol. 2014;21:768–74.CrossRef
18.
go back to reference Glazer HS, Kaiser LR, Anderson DJ, Molina PL, Emami B, Roper CL, et al. Indeterminate mediastinal invasion in bronchogenic carcinoma: CT evaluation. Radiology. 1989;173:37–42.CrossRefPubMed Glazer HS, Kaiser LR, Anderson DJ, Molina PL, Emami B, Roper CL, et al. Indeterminate mediastinal invasion in bronchogenic carcinoma: CT evaluation. Radiology. 1989;173:37–42.CrossRefPubMed
19.
go back to reference Herman SJ, Winton TL, Weisbrod GL, Towers MJ, Mentzer SJ. Mediastinal invasion by bronchogenic carcinoma: CT signs. Radiology. 1994;190:841–6.CrossRefPubMed Herman SJ, Winton TL, Weisbrod GL, Towers MJ, Mentzer SJ. Mediastinal invasion by bronchogenic carcinoma: CT signs. Radiology. 1994;190:841–6.CrossRefPubMed
20.
go back to reference White PG, Adams H, Crane MD, Butchart EG. Preoperative staging of carcinoma of the bronchus: can computed tomographic scanning reliably identify stage III tumours? Thorax. 1994;49:951–7.CrossRefPubMedPubMedCentral White PG, Adams H, Crane MD, Butchart EG. Preoperative staging of carcinoma of the bronchus: can computed tomographic scanning reliably identify stage III tumours? Thorax. 1994;49:951–7.CrossRefPubMedPubMedCentral
21.
go back to reference Shimamoto H, Iwano S, Umakoshi H, Kawaguchi K, Naganawa S. Evaluation of locoregional invasiveness of small-sized non-small cell lung cancers by enhanced dual-energy computed tomography. Cancer Imaging. 2016;16:18.CrossRefPubMedPubMedCentral Shimamoto H, Iwano S, Umakoshi H, Kawaguchi K, Naganawa S. Evaluation of locoregional invasiveness of small-sized non-small cell lung cancers by enhanced dual-energy computed tomography. Cancer Imaging. 2016;16:18.CrossRefPubMedPubMedCentral
22.
go back to reference Ohno Y, Koyama H, Lee HY, Miura S, Yoshikawa T, Sugimura K. Contrast-enhanced CT and MRI-based perfusion assessment for pulmonary diseases: basics and clinical applications. Diagn Interv Radiol. 2016;22:407–21.CrossRefPubMedPubMedCentral Ohno Y, Koyama H, Lee HY, Miura S, Yoshikawa T, Sugimura K. Contrast-enhanced CT and MRI-based perfusion assessment for pulmonary diseases: basics and clinical applications. Diagn Interv Radiol. 2016;22:407–21.CrossRefPubMedPubMedCentral
23.
go back to reference Konert T, Vogel W, MacManus MP, Nestle U, Belderbos J, Grégoire V, et al. PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. Radiother Oncol. 2015;116:27–34.CrossRefPubMed Konert T, Vogel W, MacManus MP, Nestle U, Belderbos J, Grégoire V, et al. PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. Radiother Oncol. 2015;116:27–34.CrossRefPubMed
24.
go back to reference Treglia G, Sadeghi R, Annunziata S, Lococo F, Cafarotti S, Prior JO, et al. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the assessment of pleural abnormalities in cancer patients: a systematic review and a meta-analysis. Lung Cancer. 2014;83:1–7.CrossRefPubMed Treglia G, Sadeghi R, Annunziata S, Lococo F, Cafarotti S, Prior JO, et al. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the assessment of pleural abnormalities in cancer patients: a systematic review and a meta-analysis. Lung Cancer. 2014;83:1–7.CrossRefPubMed
25.
go back to reference Hollingdale AE, Roques TW, Curtin J, Martin WM, Horan G, Barrett A. Multidisciplinary collaborative gross tumour volume definition for lung cancer radiotherapy: a prospective study. Cancer Imaging. 2011;11:202–8.PubMedPubMedCentral Hollingdale AE, Roques TW, Curtin J, Martin WM, Horan G, Barrett A. Multidisciplinary collaborative gross tumour volume definition for lung cancer radiotherapy: a prospective study. Cancer Imaging. 2011;11:202–8.PubMedPubMedCentral
26.
go back to reference Broncano J, Luna A, Sánchez-González J, Alvarez-Kindelan A, Bhalla S. Functional MRI imaging in chest malignancies. Magn Reson Imaging Clin N Am. 2016;24:135–55.CrossRefPubMed Broncano J, Luna A, Sánchez-González J, Alvarez-Kindelan A, Bhalla S. Functional MRI imaging in chest malignancies. Magn Reson Imaging Clin N Am. 2016;24:135–55.CrossRefPubMed
27.
go back to reference Usuda K, Sagawa M, Maeda S, Motono N, Tanaka M, Machida Y, et al. Diagnostic performance of whole-body diffusion-weighted imaging compared to PET-CT plus brain MRI in staging clinically resectable lung cancer. Asian Pac J Cancer Prev. 2016;17:2775–80.PubMed Usuda K, Sagawa M, Maeda S, Motono N, Tanaka M, Machida Y, et al. Diagnostic performance of whole-body diffusion-weighted imaging compared to PET-CT plus brain MRI in staging clinically resectable lung cancer. Asian Pac J Cancer Prev. 2016;17:2775–80.PubMed
28.
go back to reference Lee SM, Goo JM, Park CM, Yoon SH, Paeng JC, Cheon GJ, et al. Preoperative staging of non-small cell lung cancer: prospective comparison of PET/MRI and PET/CT. Eur Radiol. 2016;26:3850–7.CrossRefPubMed Lee SM, Goo JM, Park CM, Yoon SH, Paeng JC, Cheon GJ, et al. Preoperative staging of non-small cell lung cancer: prospective comparison of PET/MRI and PET/CT. Eur Radiol. 2016;26:3850–7.CrossRefPubMed
29.
go back to reference Ohno Y, Koyama H, Yoshikawa T, Takenaka D, Seki S, Yui M, et al. Three-way comparison of whole-body MRI, coregistered whole-body FDG PET/MRI, and integrated whole-body FDG PET/CT imaging: TNM and stage assessment capability for non-small cell lung cancer patients. Radiology. 2015;275:849–61.CrossRefPubMed Ohno Y, Koyama H, Yoshikawa T, Takenaka D, Seki S, Yui M, et al. Three-way comparison of whole-body MRI, coregistered whole-body FDG PET/MRI, and integrated whole-body FDG PET/CT imaging: TNM and stage assessment capability for non-small cell lung cancer patients. Radiology. 2015;275:849–61.CrossRefPubMed
30.
go back to reference McLoud TC, Bourgouin PM, Greenberg RW, Kosiuk JP, Templeton PA, Shepard JA, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology. 1992;182:319–23.CrossRefPubMed McLoud TC, Bourgouin PM, Greenberg RW, Kosiuk JP, Templeton PA, Shepard JA, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology. 1992;182:319–23.CrossRefPubMed
31.
go back to reference Gross BH, et al. Bronchogenic carcinoma metastatic to normal sized lymph nodes: frequency and significance. Radiology. 1986;166:71–4.CrossRef Gross BH, et al. Bronchogenic carcinoma metastatic to normal sized lymph nodes: frequency and significance. Radiology. 1986;166:71–4.CrossRef
32.
go back to reference Schmidt-Bindert G, et al. Functional imaging of lung cancer using dual energy CT: how does ionated related attenuation correlate with standarized uptake value of 18FDG-PET-CT? Eur Radiol. 2012;22:93–103.CrossRef Schmidt-Bindert G, et al. Functional imaging of lung cancer using dual energy CT: how does ionated related attenuation correlate with standarized uptake value of 18FDG-PET-CT? Eur Radiol. 2012;22:93–103.CrossRef
33.
go back to reference Darling GE, Maziak DE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol. 2011;6:1367–72.CrossRefPubMed Darling GE, Maziak DE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol. 2011;6:1367–72.CrossRefPubMed
34.
go back to reference Landau DB, Ahmad S, O’Doherty M, Treasure T. PET-based mapping of lymph node spread in lung cancer (NSCLC). J Clin Oncol. 2004;22(14 suppl):7187.CrossRef Landau DB, Ahmad S, O’Doherty M, Treasure T. PET-based mapping of lymph node spread in lung cancer (NSCLC). J Clin Oncol. 2004;22(14 suppl):7187.CrossRef
35.
go back to reference Deppen S, Putnam JB Jr, Andrade G, Speroff T, Nesbitt JC, Lambright ES, et al. Accuracy of FDG-PET in diagnose lung cancer in a region of endemic granulomatous disease. Ann Thorac Surg. 2011;92:428–32.CrossRefPubMedPubMedCentral Deppen S, Putnam JB Jr, Andrade G, Speroff T, Nesbitt JC, Lambright ES, et al. Accuracy of FDG-PET in diagnose lung cancer in a region of endemic granulomatous disease. Ann Thorac Surg. 2011;92:428–32.CrossRefPubMedPubMedCentral
36.
go back to reference Gomez-Caro A, Boada M, Cabañas M, et al. False negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cl stage non-small cell lung cancer. Eur J Cardiothorac Surg. 2002;42:93–100.CrossRef Gomez-Caro A, Boada M, Cabañas M, et al. False negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cl stage non-small cell lung cancer. Eur J Cardiothorac Surg. 2002;42:93–100.CrossRef
37.
go back to reference Lee PC, Port JL, Korst RJ, Liss Y, Meherally DN, Altorki NK. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg. 2007;84:177–81.CrossRefPubMed Lee PC, Port JL, Korst RJ, Liss Y, Meherally DN, Altorki NK. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg. 2007;84:177–81.CrossRefPubMed
38.
go back to reference Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRefPubMed Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRefPubMed
39.
go back to reference Takenaka D, Ohno Y, Hatabu H, Ohbayashi C, Yoshimura M, Ohkita Y, et al. Differentiation of metastatic versus non-metastatic mediastinal lymph nodes in patients with non-small cell lung cancer using respiratory-triggered short inversion time inversion recovery (STIR) turbo spin-echo MRI imaging. Eur J Radiol. 2002;44:216–24.CrossRefPubMed Takenaka D, Ohno Y, Hatabu H, Ohbayashi C, Yoshimura M, Ohkita Y, et al. Differentiation of metastatic versus non-metastatic mediastinal lymph nodes in patients with non-small cell lung cancer using respiratory-triggered short inversion time inversion recovery (STIR) turbo spin-echo MRI imaging. Eur J Radiol. 2002;44:216–24.CrossRefPubMed
40.
go back to reference Paul NS, Ley S, Metser U. Optimal imaging protocols for lung cancer staging: CT, PET, MR imaging, and the role of imaging. Radiol Clin North Am. 2012;50:935–49.CrossRefPubMed Paul NS, Ley S, Metser U. Optimal imaging protocols for lung cancer staging: CT, PET, MR imaging, and the role of imaging. Radiol Clin North Am. 2012;50:935–49.CrossRefPubMed
41.
go back to reference MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:287–93 (Internet).CrossRefPubMed MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:287–93 (Internet).CrossRefPubMed
42.
go back to reference Rodrigues M, Stark H, Rendl G, Rettenbacher L, Datz L, Studnicka M, et al. Diagnostic performance of [18F] FDG PET-CT compared to bone scintigraphy for the detection of bone metastases in lung cancer patients. Q J Nucl Med Mol Imaging. 2016;60:62–8.PubMed Rodrigues M, Stark H, Rendl G, Rettenbacher L, Datz L, Studnicka M, et al. Diagnostic performance of [18F] FDG PET-CT compared to bone scintigraphy for the detection of bone metastases in lung cancer patients. Q J Nucl Med Mol Imaging. 2016;60:62–8.PubMed
43.
go back to reference Usmanij EA, de Geus-Oei LF, Bussink J, Oyen WJG. Update on F-18-fluoro-deoxy-glucose-PET/computed tomography in nonsmall cell lung cancer. Curr Opin Pulm Med. 2015;21:314–21.CrossRefPubMed Usmanij EA, de Geus-Oei LF, Bussink J, Oyen WJG. Update on F-18-fluoro-deoxy-glucose-PET/computed tomography in nonsmall cell lung cancer. Curr Opin Pulm Med. 2015;21:314–21.CrossRefPubMed
44.
go back to reference Li J, Xu W, Kong F, Sun X, Zuo X. Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients. Surg Oncol. 2013;22:151–5.CrossRefPubMed Li J, Xu W, Kong F, Sun X, Zuo X. Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients. Surg Oncol. 2013;22:151–5.CrossRefPubMed
45.
go back to reference Liu T, Xu J-Y, Xu W, Bai Y-R, Yan W-L, Yang H-L. Fluorine-18 deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best? A meta-analysis. Clin Oncol (R Coll Radiol). 2011;23:350–8.CrossRef Liu T, Xu J-Y, Xu W, Bai Y-R, Yan W-L, Yang H-L. Fluorine-18 deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best? A meta-analysis. Clin Oncol (R Coll Radiol). 2011;23:350–8.CrossRef
46.
go back to reference Huellner MW, de Galiza Barbosa F, Hursmann L, Pietsch CM, Mader CE, Burger IA, et al. TNM staging of non-small cell lung cancer: comparison of PET/MR and PET/CT. J Nucl Med. 2016;57:21–6.CrossRefPubMed Huellner MW, de Galiza Barbosa F, Hursmann L, Pietsch CM, Mader CE, Burger IA, et al. TNM staging of non-small cell lung cancer: comparison of PET/MR and PET/CT. J Nucl Med. 2016;57:21–6.CrossRefPubMed
47.
go back to reference Schaefer AO, Langer M, Baumann T. Continuously moving table MRI in oncology. Rofo. 2010;182:954–64.CrossRefPubMed Schaefer AO, Langer M, Baumann T. Continuously moving table MRI in oncology. Rofo. 2010;182:954–64.CrossRefPubMed
48.
go back to reference Lauenstein TC, Goehde SC, Herborn CU, Goyen M, Oberhoff C, Debatin JF, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology. 2004;233:139–48.CrossRefPubMed Lauenstein TC, Goehde SC, Herborn CU, Goyen M, Oberhoff C, Debatin JF, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology. 2004;233:139–48.CrossRefPubMed
49.
go back to reference Sun JM, Ahn MJ, Park MJ, Yi JH, Kim TS, Chung MJ, et al. Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2010;69:105–9.CrossRefPubMed Sun JM, Ahn MJ, Park MJ, Yi JH, Kim TS, Chung MJ, et al. Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2010;69:105–9.CrossRefPubMed
50.
go back to reference Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F] fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–82.CrossRefPubMed Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F] fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–82.CrossRefPubMed
51.
go back to reference Wahl RL, Jacene H. KasamonY, LodgeMA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S.CrossRefPubMedPubMedCentral Wahl RL, Jacene H. KasamonY, LodgeMA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S.CrossRefPubMedPubMedCentral
52.
go back to reference Ziai D, Wagner T, El Badaoui A, Hitzel A, Woillard JB, Melloni B, et al. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria. Cancer Imaging. 2013;13:73–80.CrossRefPubMedPubMedCentral Ziai D, Wagner T, El Badaoui A, Hitzel A, Woillard JB, Melloni B, et al. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria. Cancer Imaging. 2013;13:73–80.CrossRefPubMedPubMedCentral
53.
go back to reference Caulo A, Mirsadraee S, Maggi F, Leccisotti L, van Beek EJ, Bonomo L. Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria. Eur Radiol. 2012;22:588–606.CrossRefPubMed Caulo A, Mirsadraee S, Maggi F, Leccisotti L, van Beek EJ, Bonomo L. Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria. Eur Radiol. 2012;22:588–606.CrossRefPubMed
54.
go back to reference Gorenberg M, Bar-Shalom R, Israel O. Patterns of FDG uptake in post-thoracotomy surgical scars in patients with lung cancer. Br J Radiol. 2008;81:821–5.CrossRefPubMed Gorenberg M, Bar-Shalom R, Israel O. Patterns of FDG uptake in post-thoracotomy surgical scars in patients with lung cancer. Br J Radiol. 2008;81:821–5.CrossRefPubMed
55.
go back to reference Choi SH, Kim YT, Kim SK, Kang KW, Goo JM, Kang CH, et al. Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer. Ann Thorac Surg. 2011;92:1826–32.CrossRefPubMed Choi SH, Kim YT, Kim SK, Kang KW, Goo JM, Kang CH, et al. Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer. Ann Thorac Surg. 2011;92:1826–32.CrossRefPubMed
56.
go back to reference Larici AR, Del Ciello A, Maggi F, Santoro SI, Meduri B, Valentini V, et al. Lung abnormalities at multimodality imaging after radiation therapy for non- small cell lung cancer. Radiographics. 2011;31:771–89.CrossRefPubMed Larici AR, Del Ciello A, Maggi F, Santoro SI, Meduri B, Valentini V, et al. Lung abnormalities at multimodality imaging after radiation therapy for non- small cell lung cancer. Radiographics. 2011;31:771–89.CrossRefPubMed
57.
go back to reference de Cabanyes Candela S, Detterbeck FC. A systematic review of restaging after induction therapy for stage IIa lung cancer. J Thorac Oncol. 2010;5:389–98.CrossRef de Cabanyes Candela S, Detterbeck FC. A systematic review of restaging after induction therapy for stage IIa lung cancer. J Thorac Oncol. 2010;5:389–98.CrossRef
58.
go back to reference Barnett SA, Downey RJ, Zheng J, Plourde G, Shen R, Chaft J, et al. Utility of routine PET imaging to predict response and survival after induction therapy for non-small cell lung cancer. Ann Thorac Surg. 2016;101:1052–9.CrossRefPubMedPubMedCentral Barnett SA, Downey RJ, Zheng J, Plourde G, Shen R, Chaft J, et al. Utility of routine PET imaging to predict response and survival after induction therapy for non-small cell lung cancer. Ann Thorac Surg. 2016;101:1052–9.CrossRefPubMedPubMedCentral
59.
go back to reference van Gool MH, Aukema TS, Hartemink KJ, Valdés Olmos RA, van Tinteren H, Klomp HM. FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. World J Radiol. 2014;6:392–8.CrossRefPubMedPubMedCentral van Gool MH, Aukema TS, Hartemink KJ, Valdés Olmos RA, van Tinteren H, Klomp HM. FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. World J Radiol. 2014;6:392–8.CrossRefPubMedPubMedCentral
61.
go back to reference Weller A, O’Brien ME, Ahmed M, Popat S, Bhosle J, McDonald F, et al. Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. Eur J Cancer. 2016;59:65–78.CrossRefPubMed Weller A, O’Brien ME, Ahmed M, Popat S, Bhosle J, McDonald F, et al. Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. Eur J Cancer. 2016;59:65–78.CrossRefPubMed
62.
go back to reference Ohno Y, Fujisawa Y, Koyama H, Kishida Y, Seki S, Sugihara N, et al. Dynamic contrast-enhanced perfusion area-detector CT assessed with various mathematical models: its capability for therapeutic outcome prediction for non-small cell lung cancer patients with chemoradiotherapy as compared with that of FDG-PET/CT. Eur J Radiol. 2017;86:83–91.CrossRefPubMed Ohno Y, Fujisawa Y, Koyama H, Kishida Y, Seki S, Sugihara N, et al. Dynamic contrast-enhanced perfusion area-detector CT assessed with various mathematical models: its capability for therapeutic outcome prediction for non-small cell lung cancer patients with chemoradiotherapy as compared with that of FDG-PET/CT. Eur J Radiol. 2017;86:83–91.CrossRefPubMed
64.
go back to reference Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11:102–25.CrossRefPubMedPubMedCentral Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11:102–25.CrossRefPubMedPubMedCentral
65.
go back to reference Tsuchida T, Morikawa M, Demura Y, Umeda Y, Okazawa H, Kimura H. Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography. J Magn Reson Imaging. 2013;38:80–8.CrossRefPubMed Tsuchida T, Morikawa M, Demura Y, Umeda Y, Okazawa H, Kimura H. Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography. J Magn Reson Imaging. 2013;38:80–8.CrossRefPubMed
66.
go back to reference Ohno Y, Nogami M, Higashino T, Takenaka D, Matsumoto S, Hatabu H, et al. Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy. J Magn Reson Imaging. 2005;21:775–83.CrossRefPubMed Ohno Y, Nogami M, Higashino T, Takenaka D, Matsumoto S, Hatabu H, et al. Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy. J Magn Reson Imaging. 2005;21:775–83.CrossRefPubMed
67.
go back to reference Schwenzer NF, Schraml C, Müller M, Brendle C, Sauter A, Spengler W, et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging—pilot study. Radiology. 2012;264:551–8.CrossRefPubMed Schwenzer NF, Schraml C, Müller M, Brendle C, Sauter A, Spengler W, et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging—pilot study. Radiology. 2012;264:551–8.CrossRefPubMed
69.
go back to reference Ohno Y, Koyama H, Yoshikawa T, Matsumoto K, Aoyama N, Onishi Y, et al. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. AJR Am J Roentgenol. 2012;198:75–82.CrossRefPubMed Ohno Y, Koyama H, Yoshikawa T, Matsumoto K, Aoyama N, Onishi Y, et al. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. AJR Am J Roentgenol. 2012;198:75–82.CrossRefPubMed
70.
go back to reference Novello S, Giaj Levra M, Vavala T. Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: a review of existing evidence. Crit Rev Oncol Hematol. 2012;83:208–15.CrossRefPubMed Novello S, Giaj Levra M, Vavala T. Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: a review of existing evidence. Crit Rev Oncol Hematol. 2012;83:208–15.CrossRefPubMed
71.
go back to reference Zhou H, Zhang Z, Denney R, Williams JS, Gerberich J, Stojadinovic S, Saha D, Shelton JM, Mason RP. Tumor physiological changes during hypofractionated stereotactic body radiation therapy assessed using multi-parametric magnetic resonance imaging. Oncotarget. 2017;8:37464–77.PubMedPubMedCentral Zhou H, Zhang Z, Denney R, Williams JS, Gerberich J, Stojadinovic S, Saha D, Shelton JM, Mason RP. Tumor physiological changes during hypofractionated stereotactic body radiation therapy assessed using multi-parametric magnetic resonance imaging. Oncotarget. 2017;8:37464–77.PubMedPubMedCentral
72.
go back to reference de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med. 2011;5:48–55.CrossRef de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med. 2011;5:48–55.CrossRef
73.
go back to reference van Gool MH, Aukema TS, Schaake EE, Rijna H, Codrington HE, Valdes Olmos RA, et al. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer. Ann Surg Oncol. 2014;2:2831–7.CrossRef van Gool MH, Aukema TS, Schaake EE, Rijna H, Codrington HE, Valdes Olmos RA, et al. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer. Ann Surg Oncol. 2014;2:2831–7.CrossRef
74.
go back to reference Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16:990–8.CrossRefPubMed Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16:990–8.CrossRefPubMed
75.
go back to reference Socinski MA. Incorporating immunotherapy into the treatment of non-small cell lung cancer: practical guidance for the clinic. Semin Oncol. 2015;42(Suppl 2):S19–28.CrossRefPubMed Socinski MA. Incorporating immunotherapy into the treatment of non-small cell lung cancer: practical guidance for the clinic. Semin Oncol. 2015;42(Suppl 2):S19–28.CrossRefPubMed
76.
go back to reference Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.CrossRefPubMed Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.CrossRefPubMed
77.
go back to reference Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510–7.CrossRefPubMedPubMedCentral Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510–7.CrossRefPubMedPubMedCentral
78.
go back to reference Carreras-Delgado JL, Pérez-Dueñas V, Riola-Parada C, García Cañamaque L. PET/RM ¿un lujo o una necesidad? Rev Esp Med Nucl Imagen Mol. 2016;35:313–20.PubMed Carreras-Delgado JL, Pérez-Dueñas V, Riola-Parada C, García Cañamaque L. PET/RM ¿un lujo o una necesidad? Rev Esp Med Nucl Imagen Mol. 2016;35:313–20.PubMed
79.
go back to reference Schwenzer NF, Seith F, Gatidis S, Brendle C, Schmidt H, Pfannenberg CA, et al. Diagnosing lung nodules on oncologic MR/PET imaging: comparison of fast T1-weighted sequences and influence of image acquisition in inspiration and expiration breath-hold. Korean J Radiol. 2016;17:684–94.CrossRefPubMedPubMedCentral Schwenzer NF, Seith F, Gatidis S, Brendle C, Schmidt H, Pfannenberg CA, et al. Diagnosing lung nodules on oncologic MR/PET imaging: comparison of fast T1-weighted sequences and influence of image acquisition in inspiration and expiration breath-hold. Korean J Radiol. 2016;17:684–94.CrossRefPubMedPubMedCentral
80.
go back to reference Raad RA, Friedman KP, Heacock L, Ponzo F, Melsaether A, Chandarana H. Outcome of small lung nodules missed on hybrid PET/MRI in patients with primary malignancy. J Magn Reson Imaging. 2016;43:504–11.CrossRefPubMed Raad RA, Friedman KP, Heacock L, Ponzo F, Melsaether A, Chandarana H. Outcome of small lung nodules missed on hybrid PET/MRI in patients with primary malignancy. J Magn Reson Imaging. 2016;43:504–11.CrossRefPubMed
81.
go back to reference Riola-Parada C, García-Cañamaque L, Pérez-Dueñas V, Garcerant-Tafur M, Carreras-Delgado JL. PET/RM simultanea vs PET/TC en oncología. Una revisión sistemática. Rev Esp Med Nucl Imagen Mol. 2016;35:306–12.PubMed Riola-Parada C, García-Cañamaque L, Pérez-Dueñas V, Garcerant-Tafur M, Carreras-Delgado JL. PET/RM simultanea vs PET/TC en oncología. Una revisión sistemática. Rev Esp Med Nucl Imagen Mol. 2016;35:306–12.PubMed
Metadata
Title
SEOM–SERAM–SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer
Authors
G. Fernández-Pérez
R. Sánchez-Escribano
A. M. García-Vicente
A. Luna-Alcalá
J. Ceballos-Viro
R. C. Delgado-Bolton
J. C. Vilanova-Busquets
P. Sánchez-Rovira
M. P. Fierro-Alanis
R. García-Figueiras
J. E. Alés-Martínez
Publication date
01-07-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 7/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1795-y

Other articles of this Issue 7/2018

Clinical and Translational Oncology 7/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine